{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:54:40Z","timestamp":1783828480121,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T00:00:00Z","timestamp":1709337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Human herpesviruses are widespread among the human population. The infections often occur unnoticed, but severe disease as well as long-term sequelae are part of the symptom spectrum. The prevalence varies among subpopulations and with time. The aim of this study was to describe the seroprevalence of Immunoglobulin G against <jats:italic>Herpes simplex 1<\/jats:italic>, <jats:italic>Herpes simplex 2<\/jats:italic>, Epstein-Barr virus and Cytomegalovirus in the adult Swedish population over a time period of several decades.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Serum samples (<jats:italic>n<\/jats:italic>\u2009=\u2009892) from biobanks, originating from 30-year-old women, 50-year-old men and 50-year-old women sampled between 1975 and 2018, were analyzed for presence of anti-herpesvirus antibodies. Linear regression analysis was used to test for a correlation between birth year and seroprevalence. Multiple linear regression analysis was used to differentiate between other factors such as age and gender.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Birth year correlated negatively with the prevalence of immunoglobulin G against <jats:italic>Herpes simplex 1<\/jats:italic> and Epstein-Barr virus (<jats:italic>p<\/jats:italic>\u2009=\u20090.004 and 0.033), and positively with Immunoglobulin G against Cytomegalovirus (<jats:italic>p<\/jats:italic>\u2009=\u20090.039). When participant categories were analyzed separately, birth year correlated negatively with the prevalence of Immunoglobulin G against <jats:italic>Herpes simplex 1 and Herpes simplex 2<\/jats:italic> (<jats:italic>p<\/jats:italic>\u2009=\u20090.032 and 0.028) in 30-year-old women, and with the prevalence of Immunoglobulin G against Cytomegalovirus in 50-year-old men (<jats:italic>p<\/jats:italic>\u2009=\u20090.011).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The prevalence of Immunoglobulin G against <jats:italic>Herpes simplex 1<\/jats:italic>, <jats:italic>Herpes simplex 2<\/jats:italic> and Epstein-Barr virus decreases in later birth cohorts. This indicates a trend of declining risk of getting infected with these viruses as a child and adolescent.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09155-w","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T09:02:13Z","timestamp":1709370133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time trends in herpesvirus seroepidemiology among Swedish adults"],"prefix":"10.1186","volume":"24","author":[{"given":"Jan","family":"Olsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Nourmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Honkala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6ran","family":"Hallmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Weidung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"L\u00f6vheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Elgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"9155_CR1","unstructured":"Arvin, A., et al., Human Herpesviruses Biology, Therapy, and Immunoprophylaxis. 2007, Cambridge University Press,: Cambridge. p. 1 online resource (1408 p.)."},{"issue":"1","key":"9155_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1750-9378-9-38","volume":"9","author":"G Khan","year":"2014","unstructured":"Khan G, Hashim MJ. Global burden of deaths from Epstein-Barr virus attributable malignancies 1990\u20132010. Infect Agent Cancer. 2014;9(1):38.","journal-title":"Infect Agent Cancer"},{"issue":"10","key":"9155_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrc2888","volume":"10","author":"EA Mesri","year":"2010","unstructured":"Mesri EA, Cesarman E, Boshoff C. Kaposi\u2019s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707\u201319.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"9155_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13(1):25\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"9155_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jalz.2014.04.522","volume":"11","author":"H Lovheim","year":"2015","unstructured":"Lovheim H, et al. Reactivated herpes simplex infection increases the risk of Alzheimer\u2019s disease. Alzheimers Dement. 2015;11(6):593\u20139.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"9155_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/JAD-171162","volume":"67","author":"H Lovheim","year":"2019","unstructured":"Lovheim H, et al. Herpes Simplex Virus, APOEvarepsilon4, and Cognitive Decline in Old Age: Results from the Betula Cohort Study. J Alzheimers Dis. 2019;67(1):211\u201320.","journal-title":"J Alzheimers Dis"},{"key":"9155_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.trci.2019.09.014","volume":"5","author":"K Lopatko Lindman","year":"2019","unstructured":"Lopatko Lindman K, et al. A genetic signature including apolipoprotein E\u03b54 potentiates the risk of herpes simplex\u2013associated Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: Translational Research & Clinical Interventions. 2019;5:697\u2013704.","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"3","key":"9155_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3233\/JAD-161305","volume":"61","author":"H Lovheim","year":"2018","unstructured":"Lovheim H, et al. Interaction between Cytomegalovirus and Herpes Simplex Virus Type 1 Associated with the Risk of Alzheimer\u2019s Disease Development. J Alzheimers Dis. 2018;61(3):939\u201345.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"9155_CR9","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/ene.14597","volume":"28","author":"M Bistrom","year":"2021","unstructured":"Bistrom M, et al. Epstein-Barr virus infection after adolescence and human herpesvirus 6A as risk factors for multiple sclerosis. Eur J Neurol. 2021;28(2):579\u201386.","journal-title":"Eur J Neurol"},{"key":"9155_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.603309","volume":"11","author":"K Asha","year":"2021","unstructured":"Asha K, Sharma-Walia N. Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections. Front Cell Infect Microbiol. 2021;11: 603309.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"9155_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001709","volume":"20","author":"I Busnadiego","year":"2022","unstructured":"Busnadiego I, et al. Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol. 2022;20(7): e3001709.","journal-title":"PLoS Biol"},{"issue":"3","key":"9155_CR12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"L Henze","year":"2022","unstructured":"Henze L, et al. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus. Ann Hematol. 2022;101(3):491\u2013511.","journal-title":"Ann Hematol"},{"issue":"3","key":"9155_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/02841860701203545","volume":"46","author":"E Pukkala","year":"2007","unstructured":"Pukkala E, et al. Nordic biological specimen banks as basis for studies of cancer causes and control\u2013more than 2 million sample donors, 25 million person years and 100,000 prospective cancers. Acta Oncol. 2007;46(3):286\u2013307.","journal-title":"Acta Oncol"},{"key":"9155_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/14034950310001432","volume":"61","author":"G Hallmans","year":"2003","unstructured":"Hallmans G, et al. Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort - evaluation of risk factors and their interactions. Scand J Public Health Suppl. 2003;61:18\u201324.","journal-title":"Scand J Public Health Suppl"},{"key":"9155_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12979-017-0093-4","volume":"14","author":"J Olsson","year":"2017","unstructured":"Olsson J, et al. Herpes virus seroepidemiology in the adult Swedish population. Immun Ageing. 2017;14:10.","journal-title":"Immun Ageing"},{"key":"9155_CR16","doi-asserted-by":"crossref","unstructured":"Esberg A, et al. 43-Year Temporal Trends in Immune Response to Oral Bacteria in a Swedish Population. Pathogens. 2020;9(7):544.","DOI":"10.3390\/pathogens9070544"},{"issue":"6","key":"9155_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jalz.2014.07.157","volume":"11","author":"H Lovheim","year":"2015","unstructured":"Lovheim H, et al. Herpes simplex infection and the risk of Alzheimer\u2019s disease: A nested case-control study. Alzheimers Dement. 2015;11(6):587\u201392.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"9155_CR18","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10552-011-9799-3","volume":"22","author":"S Sjostrom","year":"2011","unstructured":"Sjostrom S, et al. Human immunoglobulin G levels of viruses and associated glioma risk. Cancer Causes Control. 2011;22(9):1259\u201366.","journal-title":"Cancer Causes Control"},{"issue":"12","key":"9155_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/OLQ.0000000000000689","volume":"44","author":"E Agyemang","year":"2017","unstructured":"Agyemang E, et al. Performance of Commercial Enzyme-Linked Immunoassays for Diagnosis of Herpes Simplex Virus-1 and Herpes Simplex Virus-2 Infection in a Clinical Setting. Sex Transm Dis. 2017;44(12):763\u20137.","journal-title":"Sex Transm Dis"},{"issue":"6","key":"9155_CR20","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/j.1469-0691.2004.00836.x","volume":"10","author":"R Ashley-Morrow","year":"2004","unstructured":"Ashley-Morrow R, et al. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. Clin Microbiol Infect. 2004;10(6):530\u20136.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"9155_CR21","first-page":"78","volume":"10","author":"BC Gartner","year":"2003","unstructured":"Gartner BC, et al. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin Diagn Lab Immunol. 2003;10(1):78\u201382.","journal-title":"Clin Diagn Lab Immunol"},{"issue":"1","key":"9155_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.0042-9007.2004.00388.x","volume":"86","author":"M Hecker","year":"2004","unstructured":"Hecker M, et al. Continuous cytomegalovirus seroconversion in a large group of healthy blood donors. Vox Sang. 2004;86(1):41\u20134.","journal-title":"Vox Sang"},{"issue":"7","key":"9155_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200267","volume":"13","author":"R Lachmann","year":"2018","unstructured":"Lachmann R, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS ONE. 2018;13(7): e0200267.","journal-title":"PLoS ONE"},{"issue":"5","key":"9155_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3109\/23744235.2015.1123290","volume":"48","author":"L Puhakka","year":"2016","unstructured":"Puhakka L, et al. Decrease in seroprevalence for herpesviruses among pregnant women in Finland: cross-sectional study of three time points 1992, 2002 and 2012. Infect Dis (Lond). 2016;48(5):406\u201310.","journal-title":"Infect Dis (Lond)"},{"issue":"5","key":"9155_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215553","volume":"14","author":"H Forbes","year":"2019","unstructured":"Forbes H, et al. Risk factors for herpes simplex virus type-1 infection and reactivation: Cross-sectional studies among EPIC-Norfolk participants. PLoS ONE. 2019;14(5): e0215553.","journal-title":"PLoS ONE"},{"issue":"8","key":"9155_CR26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jama.296.8.964","volume":"296","author":"F Xu","year":"2006","unstructured":"Xu F, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964\u201373.","journal-title":"JAMA"},{"issue":"4","key":"9155_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.2340\/0001555570330334","volume":"70","author":"GB Lowhagen","year":"1990","unstructured":"Lowhagen GB, et al. Epidemiology of genital herpes infections in Sweden. Acta Derm Venereol. 1990;70(4):330\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"9155_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/sti.78.5.352","volume":"78","author":"K Edgardh","year":"2002","unstructured":"Edgardh K. Adolescent sexual health in Sweden. Sex Transm Infect. 2002;78(5):352\u20136.","journal-title":"Sex Transm Infect"},{"issue":"6","key":"9155_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2340\/00015555-0699","volume":"89","author":"M Berntsson","year":"2009","unstructured":"Berntsson M, et al. Decreasing prevalence of herpes simplex virus-2 antibodies in selected groups of women in Sweden. Acta Derm Venereol. 2009;89(6):623\u20136.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"9155_CR30","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1186\/s12879-022-07525-w","volume":"22","author":"K Lopatko Lindman","year":"2022","unstructured":"Lopatko Lindman K, et al. Long-term time trends in reactivated herpes simplex infections and treatment in Sweden. BMC Infect Dis. 2022;22(1):547.","journal-title":"BMC Infect Dis"},{"issue":"17","key":"9155_CR31","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1001\/jama.2022.19061","volume":"328","author":"C Johnston","year":"2022","unstructured":"Johnston C, et al. Viral Shedding 1 Year Following First-Episode Genital HSV-1 Infection. JAMA. 2022;328(17):1730\u20139.","journal-title":"JAMA"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09155-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09155-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T09:03:35Z","timestamp":1709370215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09155-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9155"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09155-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,2]]},"assertion":[{"value":"18 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by a regional ethical board (Dnr 2017\/384\u201331). The research subjects have provided informed consent for the serum- and plasma samples to be used for research purposes at the time of the sampling.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants who have provided consent for their serum\/plasma to be used in research have also given consent for publication of research based on stored serum\/plasma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}